Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 258Other hematologic neoplasm 143Plasma cell 10Myeloid 6Genitourinary 4Gastrointestinal 4CNS 4Thoracic 3Classical hematology 3Tumor-Agnostic 2Dermatologic 2Breast 2NET 1Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 2Pancreatic Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ibrutinib × Breast × Clear all
NCT03379428 2024-12-06

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

US Oncology Research

Phase 1/2 Active not recruiting
34 enrolled
Breast

Breast Neoplasms

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Pharmacyclics LLC.

Phase 1/2 Completed
124 enrolled 17 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡